Eribulin Advanz Pharma

Eribulin Mesylate is a chemotherapy medication used to treat certain types of cancer. This intravenous medication is manufactured by Advanz Pharma Limited and is available in the EU market.

Eribulin Mesylate is primarily used in the treatment of metastatic breast cancer and liposarcoma. It works by slowing or stopping the growth of cancer cells. Patients often wonder, 'What is Eribulin Mesylate used for?' This medication is typically administered intravenously and is prescribed for advanced stages of cancer.

Common effects of Eribulin Mesylate may include fatigue, nausea, and hair loss. Some patients may also experience peripheral neuropathy, which can cause tingling or numbness in the hands and feet. These effects can vary from person to person and may require monitoring by a healthcare professional.

Eribulin Mesylate should be handled with care and administered under the supervision of a healthcare professional. It is important to follow all safety guidelines when using this medication. Patients should inform their healthcare provider about any existing medical conditions or allergies before starting treatment.

Eribulin Mesylate may interact with other medications, including those that affect the liver or bone marrow. It is important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain foods may also affect the efficacy of this medication.